NASDAQ: $CMPX
Compass Therapeutics enters the second half of 2026 in a strong financial position, though its stock has recently experienced significant volatility following the long-awaited data readout for its lead program.
Cash Runway
As of the most recent financial updates in early 2026, Compass Therapeutics is exceptionally well-capitalized for a clinical-stage biotech:
- Total Cash: The company reported approximately $209 million in cash and marketable securities (as of year-end 2025/early 2026).
- Runway: This capital is projected to fund operations into 2028.
- Burn Rate: The company maintains a disciplined burn, with recent quarterly net losses hovering around $15.7 million, providing several years of “cushion” to reach further clinical milestones without immediate need for dilution based financing.
2026 Pipeline Milestones
The remainder of 2026 is focused on expanding beyond its lead biliary tract cancer (BTC) indication and moving early-stage assets into meaningful human trials.
Context for 2026
It is worth noting that in April 2026, the company released topline results for its Phase 2/3 trial in Biliary Tract Cancer. While it met the primary endpoint of Overall Response Rate (ORR) and showed progression-free survival (PFS) benefits, the stock saw a sharp “sell-the-news” reaction due to complexities in the overall survival data caused by patient crossover.
For the rest of the year, investors will be looking for regulatory clarity (i.e., will the FDA accept these results for a filing?) and the Phase 1 data from CTX-8371, which could prove whether Compass has a second “anchor” asset in its bispecific portfolio.
Do you follow CMPX primarily for the biliary tract cancer data, or are you more interested in their newer bispecific platforms?